OBJECTIVE: The goal of this study was to investigate the novel hypothesis that bone marrow kinase in the X chromosome (Bmx), an established inflammatory mediator of pathological angiogenesis, promotes lymphangiogenesis. METHODS AND RESULTS: We have recently demonstrated a critical role for Bmx in inflammatory angiogenesis. However, the role of Bmx in lymphangiogenesis has not been investigated. Here, we show that in wild-type mice, Bmx is upregulated in lymphatic vessels in response to vascular endothelial growth factor (VEGF). In comparison with wild-type mice, Bmx-deficient mice mount weaker lymphangiogenic responses to VEGF-A and VEGF-C in 2 mouse models. In vitro, Bmx is expressed in cultured human dermal microvascular lymphatic endothelial cells. Furthermore, pharmacological inhibition and short interfering RNA mediated silencing of Bmx reduces VEGF-A and VEGF-C-induced signaling and lymphatic endothelial cell tube formation. Mechanistically, we demonstrated that Bmx differentially regulates VEGFR-2 and VEGFR-3 receptor signaling pathways: Bmx associates with and directly regulates VEGFR-2 activation, whereas Bmx associates with VEGFR-3 and regulates downstream signaling without an effect on the receptor autophosphorylation. CONCLUSIONS: Our in vivo and in vitro results provide the first insight into the mechanism by which Bmx mediates VEGF-dependent lymphangiogenic signaling.
OBJECTIVE: The goal of this study was to investigate the novel hypothesis that bone marrow kinase in the X chromosome (Bmx), an established inflammatory mediator of pathological angiogenesis, promotes lymphangiogenesis. METHODS AND RESULTS: We have recently demonstrated a critical role for Bmx in inflammatory angiogenesis. However, the role of Bmx in lymphangiogenesis has not been investigated. Here, we show that in wild-type mice, Bmx is upregulated in lymphatic vessels in response to vascular endothelial growth factor (VEGF). In comparison with wild-type mice, Bmx-deficientmice mount weaker lymphangiogenic responses to VEGF-A and VEGF-C in 2 mouse models. In vitro, Bmx is expressed in cultured human dermal microvascular lymphatic endothelial cells. Furthermore, pharmacological inhibition and short interfering RNA mediated silencing of Bmx reduces VEGF-A and VEGF-C-induced signaling and lymphatic endothelial cell tube formation. Mechanistically, we demonstrated that Bmx differentially regulates VEGFR-2 and VEGFR-3 receptor signaling pathways: Bmx associates with and directly regulates VEGFR-2 activation, whereas Bmx associates with VEGFR-3 and regulates downstream signaling without an effect on the receptor autophosphorylation. CONCLUSIONS: Our in vivo and in vitro results provide the first insight into the mechanism by which Bmx mediates VEGF-dependent lymphangiogenic signaling.
Authors: Jeremy Goldman; Joseph M Rutkowski; Jacqueline D Shields; Miriella C Pasquier; Yingjie Cui; Hugo G Schmökel; Stephen Willey; Daniel J Hicklin; Bronislaw Pytowski; Melody A Swartz Journal: FASEB J Date: 2007-01-08 Impact factor: 5.191
Authors: Tuomas Tammela; Georgia Zarkada; Elisabet Wallgard; Aino Murtomäki; Steven Suchting; Maria Wirzenius; Marika Waltari; Mats Hellström; Tibor Schomber; Reetta Peltonen; Catarina Freitas; Antonio Duarte; Helena Isoniemi; Pirjo Laakkonen; Gerhard Christofori; Seppo Ylä-Herttuala; Masabumi Shibuya; Bronislaw Pytowski; Anne Eichmann; Christer Betsholtz; Kari Alitalo Journal: Nature Date: 2008-06-25 Impact factor: 49.962
Authors: Lucy A Truman; Kevin L Bentley; Elenoe C Smith; Stephanie A Massaro; David G Gonzalez; Ann M Haberman; Myriam Hill; Dennis Jones; Wang Min; Diane S Krause; Nancy H Ruddle Journal: Am J Pathol Date: 2012-02-04 Impact factor: 4.307
Authors: Peter Baluk; Alicia Adams; Keeley Phillips; Jennifer Feng; Young-Kwon Hong; Mary B Brown; Donald M McDonald Journal: Am J Pathol Date: 2014-03-11 Impact factor: 4.307
Authors: Zhao Li; Mingzhu Yin; Haifeng Zhang; Weiming Ni; Richard W Pierce; Huanjiao Jenny Zhou; Wang Min Journal: Circ Res Date: 2020-01-08 Impact factor: 17.367
Authors: Marlys H Witte; Michael T Dellinger; Cristobal M Papendieck; Francesco Boccardo Journal: Clin Exp Metastasis Date: 2012-07-15 Impact factor: 5.150